| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389676A1 Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389663A1 Protease inhibitors as modulators of periodontal wound healing |
| 05/10/2001 | CA2389655A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389574A1 Ghsr ligand polypeptides and dnas thereof |
| 05/10/2001 | CA2389543A1 Hcv ns3 protease inhibitors |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389236A1 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | CA2389058A1 Novel tumor suppressor gene |
| 05/10/2001 | CA2388955A1 Recombinant fusion molecules |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388354A1 Lactobacillus helvetius producing antihypertensive di- and tripeptides |
| 05/10/2001 | CA2387808A1 Human chemokine beta-13 |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387799A1 19 human secreted proteins |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385665A1 Modulation of enos activity and therapeutic uses thereof |
| 05/10/2001 | CA2324813A1 Combination treatment for depression and anxiety |
| 05/10/2001 | CA2324801A1 Use of apo b secretion/mtp inhibitors and anti-obesity agents |
| 05/10/2001 | CA2324800A1 Use of apo b secretion/mtp inhibitors |
| 05/09/2001 | EP1097994A2 Human bad polypeptides, encoding nucleic acids and methods of use |
| 05/09/2001 | EP1097993A2 Functional ribozyme chimeric molecules capable of sliding |
| 05/09/2001 | EP1097991A2 Human adenylate cyclase IX and use therefor |
| 05/09/2001 | EP1097989A2 Ndr phosphokinase |
| 05/09/2001 | EP1097945A2 Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| 05/09/2001 | EP1097943A1 Process for the preparation of hyperpolymers of haemoglobin with uniform molecular weight |
| 05/09/2001 | EP1097942A2 Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes |
| 05/09/2001 | EP1097941A1 Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies |
| 05/09/2001 | EP1097940A1 Tumor antigen peptide originating in sart-1 |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097717A1 Remedies for apoptosis-associated diseases |
| 05/09/2001 | EP1097716A1 Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH) |
| 05/09/2001 | EP1097714A1 Composition for use in the treatment of tumours and the immunization of humans and animals |
| 05/09/2001 | EP1097713A1 Inhibitors of the inositol polyphosphate 5-phosphatase ship-2 molecule |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097696A1 Composition containing waxes and an hydrophilic active unstable in an oxidizing medium and cosmetic use thereof |
| 05/09/2001 | EP1097241A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 05/09/2001 | EP1097234A1 Method for improving the gene transfer of genetic material in mammalian cells through the use of p21 (waf-1) |
| 05/09/2001 | EP1097233A2 Growth differentiation factor promoter and uses therefor |
| 05/09/2001 | EP1097228A1 Method of making proteins in transformed yeast cells |
| 05/09/2001 | EP1097210A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 05/09/2001 | EP1097209A2 Inhibition of alopecia |
| 05/09/2001 | EP1097208A2 Compositions and methods for therapy and diagnosis of prostate cancer |
| 05/09/2001 | EP1097207A2 Multiple splice variants of the mu-opioid receptor gene |
| 05/09/2001 | EP1097206A1 Human calcium regulatory proteins |
| 05/09/2001 | EP1097205A2 Repression of cell transformation with human pea3 |
| 05/09/2001 | EP1097203A1 Human presenilin-associated protein |
| 05/09/2001 | EP1097202A2 Human transport protein homologs |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097200A1 Pharmaceutical uses of nab1 and nab2 |
| 05/09/2001 | EP1097198A2 Soluble derivatives of anti-angiogenic peptides |
| 05/09/2001 | EP1097173A1 Peptides of il-2 and derivatives thereof and their use as therapeutic agents |
| 05/09/2001 | EP1097170A1 Growth hormone secretagogue related receptors and nucleic acids |
| 05/09/2001 | EP1097168A2 Compounds and methods for modulating cadherin-mediated functions |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1097165A1 Novel inhibitors of angiogenesis and tumor growth |
| 05/09/2001 | EP1097164A1 Processes for coupling amino acids using bis-(trichloromethyl) carbonate |
| 05/09/2001 | EP1096955A2 Cancer treatment methods using antibodies to aminophospholipids |
| 05/09/2001 | EP1096953A1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 05/09/2001 | EP1096951A1 Use of bromelain proteases for inhibiting blood coagulation |
| 05/09/2001 | EP1096950A2 Therapies using hemoproteins |
| 05/09/2001 | EP1096949A2 Treatment of celiac disease with interleukin-15 antagonists |
| 05/09/2001 | EP1096948A1 Use of interleukin-11 to treat gastrointestinal disorders |
| 05/09/2001 | EP1096947A1 Topical drug for the treatment of viral infections |
| 05/09/2001 | EP1096946A2 Delta cleavage products and methods based thereon |
| 05/09/2001 | EP1096945A1 Lysine binding fragments of angiostatin |
| 05/09/2001 | EP1096939A1 Nocathiacin antibiotics |
| 05/09/2001 | EP1096925A2 Use of inhibitors of prenyltransferases for for inhibiting fungal growth |
| 05/09/2001 | EP1096924A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 05/09/2001 | EP0730471B1 Use of lithium compounds in the treatment of cardiac insufficiency |
| 05/09/2001 | EP0684842B1 Composition for use in the treatment of tumours and the immunization of humans and animals |
| 05/09/2001 | CN1294632A Compsns. derived from i(mycobacterium vaccae) and methods for their use |
| 05/09/2001 | CN1294630A Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth |
| 05/09/2001 | CN1294597A Methods for treatment of diabetes using peptide analogues of insulin |
| 05/09/2001 | CN1294596A Method for reducing immunogenicity of proteins |
| 05/09/2001 | CN1294595A Hydrophobically-modified protein compsns, and methods |
| 05/09/2001 | CN1294517A Immunoglobulin molecules having synthetic variable region and modified specificity |
| 05/09/2001 | CN1294195A Formin protein and polynucleotide for coding it |
| 05/09/2001 | CN1294194A Actin-binding protein and polynucleotide sequence for coding it |
| 05/09/2001 | CN1294193A Human Fb65L2-2 protein and polynucleotide sequence to code it |
| 05/09/2001 | CN1294134A Polypeptide structure of shark liver for preventing and curing hepatism and its purifying process |
| 05/09/2001 | CN1294016A Injection for giving up addiction |
| 05/09/2001 | CN1294001A Uropoly acid-peptide composition |
| 05/09/2001 | CN1294000A Process for preparing uropoly acid-peptide composition |
| 05/09/2001 | CN1293959A Uropoly aic-peptide composition and its usage |
| 05/09/2001 | CN1065568C Bacteriocins from streptococcus thermophilus |
| 05/09/2001 | CN1065538C Antibiotic stalobacins |
| 05/09/2001 | CN1065438C Cyclic adhesion inhibitors |
| 05/08/2001 | US6229006 Use of antisense oligodeoxynucleotides to produce truncated proteins |
| 05/08/2001 | US6229005 DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent |
| 05/08/2001 | US6229002 Complex of nucleic acid which binds to platelet derived growth factor and nonimmunogenic, high molecular weight compound; for targeted diagnostic and therapy; anticarcinogenic agents; cardiovascular disorders; kidney disease |